Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics
GET POWR RATINGS... FREE!
RDY POWR Grades
- RDY scores best on the Stability dimension, with a Stability rank ahead of 97.19% of US stocks.
- The strongest trend for RDY is in Quality, which has been heading down over the past 47 weeks.
- RDY ranks lowest in Momentum; there it ranks in the 15th percentile.
RDY Stock Summary
- With a price/earnings ratio of 3,518.37, Dr Reddys Laboratories Ltd P/E ratio is greater than that of about 99.96% of stocks in our set with positive earnings.
- RDY's price/sales ratio is 320.1; that's higher than the P/S ratio of 98.45% of US stocks.
- As for revenue growth, note that RDY's revenue has grown -98.4% over the past 12 months; that beats the revenue growth of merely 0.84% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Dr Reddys Laboratories Ltd, a group of peers worth examining would be GBX, SSTI, FMX, NUVA, and CPIX.
- Visit RDY's SEC page to see the company's official filings. To visit the company's web site, go to www.drreddys.com.
RDY Stock Price Chart Interactive Chart >
RDY Price/Volume Stats
|Current price||$67.37||52-week high||$75.50|
|Prev. close||$66.87||52-week low||$57.54|
|Day high||$67.76||Avg. volume||155,848|
|50-day MA||$66.41||Dividend yield||0.42%|
|200-day MA||$67.21||Market Cap||11.21B|
Dr. Reddy's Laboratories Ltd (RDY) Company Bio
Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.
Most Popular Stories View All
RDY Latest News Stream
|Loading, please wait...|
RDY Latest Social Stream
View Full RDY Social Stream
Latest RDY News From Around the Web
Below are the latest news stories about Dr Reddys Laboratories Ltd that investors may wish to consider to help them evaluate RDY as an investment opportunity.
Beroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO
NEW YORK and SYDNEY, Australia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, today announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure. The approval also includes R&D overseas activities so long as the total overseas expenditure claim over the life of the R&D
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's") (NYSE: RDY) to acquire its exclusive license of E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma. E7777, an engineered IL-2-diphtheria toxin fusion protein, is an improved fo
Dr Reddy''s inks pact worth USD150 million with Citius Pharma to sell all rights to anti-cancer agent E7777
Dr Reddy''s Laboratories on Saturday said it has inked a pact with US-based Citius Pharmaceuticals to sell its rights to an anti-cancer agent.
Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)
HYDERABAD, India & PRINCETON, N.J., September 04, 2021--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. ("Citius") pursuant to which it sold all of its rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets.
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market
HYDERABAD, India & MISSISSAUGA, Ontario, September 02, 2021--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada.
RDY Price Returns
|Ex-Dividend Date||Type||Payout Amount||Change|
|Loading, please wait...|
Continue Researching RDYWant to do more research on Dr Reddys Laboratories Ltd's stock and its price? Try the links below:
Dr Reddys Laboratories Ltd (RDY) Stock Price | Nasdaq
Dr Reddys Laboratories Ltd (RDY) Stock Quote, History and News - Yahoo Finance
Dr Reddys Laboratories Ltd (RDY) Stock Price and Basic Information | MarketWatch